In the laboratory setting, researchers found Ebola relies on the human enzyme PP2A-B56 to replicate itself. By deactivating this enzyme, the team was able to successfully impede the virus’ ability to grow.
“When we inhibit the PP2A-B56 enzyme, we remove the first link in a long process, which ends with Ebola spreading,” said Jakob Nilsson, PhD, a professor of the Novo Nordisk Foundation Center for Protein Research in Copenhagen, Denmark, and one of the study’s authors. “And we can tell that it works. The Ebola infection in cell cultures where we have inhibited the PP2A-B56 enzyme is 10 times smaller after 24 hours compared to infections where we have not inhibited this enzyme.”
The researchers hope to test the enzyme-inhibiting process on animals and eventually develop a drug for humans.
More articles on infection control:
HHS inspector general: FDA is too slow on contaminated food recalls
Top 10 infection control stories, Dec. 25-29
Allied against sepsis: 5 Qs with Amplifire CEO on eliminating clinical misinformation
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.